Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Radiopharm Theranostics Ltd

RADX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: BUY

Last Close

$2.56

▼ -3.40%

Market Cap $33.66M · Vol 30.81K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$33.66M

Micro Cap

Div Yield

N/A

EPS Growth

+42.08%

YoY

RSI (14)

9.56

Momentum

Beta

N/A

vs Market

52W High

$16.25

84.25% below

52W Low

$2.45

4.49% above

Volume

30.81K

Avg 18.06K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Radiopharm Theranostics Ltd (RADX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RADX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.57%

-41.01%

-45.88%

-47.76%

YTD

-50.96%

-48.95%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$2.39M
Net Income	$-25,229,286.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-48.25% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+42.08%
Outstanding Shares	4.34B

Technical Indicators

50-Day SMA	$3.89
200-Day SMA	$4.57
RSI (14)	9.56
Beta	N/A
52-Week High	$16.25
52-Week Low	$2.45

Volume Today	30.81K
Avg Daily Volume (30D)	18.06K
Relative Volume	1.71x
Volatility (10D)	41.51
Volatility (30D)	67.84
Free Float	100.00%

Analyst Consensus

BUY

Current Price $2.56

Mean Target $14.50

52W Low$2.45 52W High$16.25

Current

Target

$2.45 $16.25

Current Analyst target

+466.41% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG01PT2ZVT9

ISINUS75041J1016

CountryAustralia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 14, 2025

TypeStocks

Instrument TypeADR American Depositary Receipt

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.